INSEPARABLE
TOGETHER
The first dual drug advanced
liposomal formulation
LONGER
Superior overall survival vs
7+3 chemotherapy in patients
with high-risk * AML
*High-risk AML defined as t-AML or AML-MRC
Indicated for: Treatment of adults with newly diagnosed,
therapy-related acute myeloid leukaemia (t-AML) or AML
with myelodysplasia-related changes (AML-MRC)
Please consult the Summary of Product Characteristics before
prescribing
Further information is available from: Jazz Pharmaceuticals Ireland,
5th Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
Legal category: POM
Information about this product, including adverse reactions,
precautions, contra-indcations and method of use can be found
at: www.ema.europa.eu/en/medicines/human/EPAR/vyxeos
www.vyxeos.eu
For country specific information please refer to your local SmPC
or Product Monograph
Adverse events should be reported. Healthcare professionals are
asked to report any suspected adverse reactions via their national
reporting system. Adverse events should also be reported by email:
[email protected] or by fax to +44 (0) 1865 598765.
AML: acute myeloid leukaemia
AML-MRC: AML with myelodysplasia-related changes
t-AML: therapy-related AML
Date of preparation: April 2019
EURW-INTVYX-0026o